LASIX

Compare LASIX  to:
Compare
Compare

Generic Name for LASIX

Furosemide 20mg, 40mg+, 80mg; tabs; +scored.

Legal Classification:

Rx

Pharmacological Class for LASIX

Diuretic (loop).

Manufacturer of LASIX

Sanofi-aventis

Indications for LASIX

Hypertension.

Adult dose for LASIX

Initially 40mg twice daily. Adding to other antihypertensives: initially reduce other agent's dose by 50%.

Children's dosing for LASIX

Not recommended.

Contraindications for LASIX

Anuria. Hepatic coma. Electrolyte depletion.

Warnings/Precautions for LASIX

Renal or hepatic dysfunction. Diabetes. Gout. SLE. Sulfonamide sensitivity. Monitor BP, electrolytes, fluids, blood, BUN. Potassium supplementation may be needed. Discontinue if progressive renal dysfunction occurs. Elderly. Pregnancy (Cat.C). Nursing mothers.

Interactions for LASIX

Digitalis, lithium toxicity. Alcohol, CNS depressants may increase orthostatic hypotension. Antagonized by indomethacin. May alter excretion of salicylates, lithium. Hypokalemia with corticosteroids, ACTH. Antagonizes tubocurarine. Potentiates antihypertensives, succinylcholine. Ototoxicity with aminoglycosides, ethacrynic acid.

Adverse Reactions for LASIX

Excessive diuresis, fluid or electrolyte imbalance, GI upset, dizziness, vertigo, paresthesias, orthostatic hypotension, hyperglycemia, jaundice, hyperuricemia, rash, photosensitivity, tinnitus, hearing loss, blood dyscrasias, renal calcification in premature infants.

How is LASIX supplied?

Tabs 20mg—100, 1000
40mg—100, 500, 1000
80mg—50, 500

Related Disease:

Hypertension

Related Resources

Tekamlo approved for hypertension

August 27, 2010

The FDA has approved Tekamlo (aliskiren and amlodipine tablets, from Novartis), a single, combination therapy tablet for the treatment of hypertension, alone or with other antihypertensive agents.

Tribenzor approved for treatment of hypertension

July 26, 2010

Daiichi Sankyo announced that the FDA has approved Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide tablets), a fixed-dose combination therapy for the treatment of hypertension in patients who are not adequately controlled on any two of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers, and diuretics.

FDA warns of dangerous ingredients in Joyful Slim herb supplement

July 22, 2010

The FDA is warning consumers that Joyful Slim herb supplement, marketed as a natural herb for weight loss, contains undeclared desmethyl sibutramine, an FDA-approved drug used as an appetite suppressant for weight loss.

FDA conducts safety review of cancer risk with angiotensin receptor blockers (ARBs)

July 15, 2010

A recently published meta-analysis combining cancer-related findings from several clinical trials is suggesting that angiotensin receptor blockers (ARBs) may be associated with a small increased risk of cancer.

FDA reviews cardiovascular mortality risk associated with Benicar

June 11, 2010

The FDA is evaluating data from two clinical trials in which patients with type 2 diabetes taking Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) had a higher rate of death from a cardiovascular cause compared to patients taking a placebo.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions